Clinical Trials Browser

lenvatinib × Gynecologic × 30 days × Clear all

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Phase 2 Recruiting

Endometrial Neoplasms

NCT04977453 2026-05-15

Keynote B59

Phase 1/2 Recruiting

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT05903833 2026-05-11

PIERCE

Phase 2 Recruiting

Vulvar Neoplasms

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT03797326 2026-05-04

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms